Also, we identified genes that were previously reported as markers of resistance of other treatments, e.g., DDIT4 was responsible for resistance to neoadjuvant chemotherapy in TNBC22, and RPS4X was found as a marker of cisplatin resistance in two breast cancer cell lines23. Here, DDIT4 is linked to breast cancer.